For our readers who enjoy learning about the newest tools and strategies in cancer research, the second installment of our series, “From the Bench,” is here. (Check out the inaugural post here.) This quarter,...
The FDA has approved the immune checkpoint inhibitor toripalimab for some patients with nasopharyngeal carcinoma. The U.S. Food and Drug Administration (FDA) has approved toripalimab-tpzi (Loqtorzi), in combination with the chemotherapies gemcitabine (Gemzar) and...
As you prepare for trick-or-treating, check out the articles selected by the editors of the 10 AACR journals for the month of October. Highlights include studies on the regulation of electrical activity between melanoma...
The FDA has approved the IDH1 inhibitor ivosidenib for a group of blood cancers harboring an IDH1 mutation. The U.S. Food and Drug Administration (FDA) has approved ivosidenib (Tibsovo) for the treatment of relapsed...
In 2021, Lillian L. Siu, MD, and Elaine R. Mardis, PhD, FAACR, each received a call from AACR Chief Executive Officer Margaret Foti, PhD, MD (hc), asking if they’d be interested in serving as...
The FDA has approved the inhibitor entrectinib for some patients 1 month of age or older with solid tumors harboring a certain genetic mutation. The U.S. Food and Drug Administration (FDA) has granted accelerated...
Immunotherapy drug approved as pre- and post-surgery treatment for non-small cell lung cancer, and bladder cancer patients who respond to chemotherapy and immunotherapy can forgo surgery.
Neuroblastoma, a rare cancer that occurs primarily in children, is a scientific paradox, said pediatric oncologist John M. Maris, MD, of Children’s Hospital of Philadelphia (CHOP). “On one hand, a fairly high percentage of...
Researchers share approaches for improving participation among underrepresented groups at AACR conference.
As the number of targeted cancer therapeutics has increased, the percentage of tumors carrying molecular alterations eligible for treatment by those drugs nearly doubled from 2017 to 2022. Precise, biomarker-guided therapies made up almost...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More